Loading
A phase 2 trial of Mirvetuximab soravtansine, Carboplatin in ovarian cancer, run by AbbVie, active and no longer recruiting.
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05456685 by AbbVie, with 125 participants enrolled, started 2022-09-28 and due to reach its primary completion in 2026-11. Interventions recorded: Mirvetuximab soravtansine, Carboplatin. Conditions listed: High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Platinum agents, Carboplatin.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Antibody-drug conjugate (ADC).
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Platinum agents, Carboplatin, Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.